Case Report

Multiple ischemic stroke with pulmonary embolism revealing severe COVID-19 infection in a young healthy patient✩,✩✩

Hicham Benramdanea,b,∗, Siham Nasria,b, Nada Ouahabia,c, Aahd Belhartia,b, Kaouthar Chehidita,a,b, Mebrouk Yassinea,c, Mebrouk Yassinea,c, Imane Skikerb,a

aFaculty of Medicine and Pharmacy, Mohammed Ist University, Oujda, Morocco
bDepartment of Radiology, Mohammed VI University Hospital Mohammed I University, Oujda, Morocco
cDepartment of Anesthesiology and Intensive Care Unit, Mohammed VI University Hospital Mohammed I University, Oujda, Morocco
dDepartment of Neurology, Mohammed VI University Hospital Mohammed I University, Oujda, Morocco

A R T I C L E   I N F O
Article history:
Received 7 June 2022
Revised 1 August 2022
Accepted 8 August 2022

Keywords:
COVID-19
Ischemic stroke
Coagulopathy
Neuroinflammation

A B S T R A C T
Coronavirus 2019 (COVID-19) disease has caused significant morbidity and mortality worldwide since its emergence in December 2019. Despite its respiratory tropism; there is a non-trivial relationship between this virus and the neurovascular system exposing patients to higher morbidity and mortality. We report the case of a young patient admitted for hemiplegia with acute respiratory failure, in whom imaging found multiple ischemic strokes with pulmonary embolism and severe involvement suggestive of COVID-19 pneumopathy. Stroke in the context of COVID-19 infection has distinct characteristics in terms of disease mechanism, patient demographics, but also clinical, biological, and neuroradiological specificities. The pathogenesis and optimal management of COVID-19-associated ischemic stroke remain unclear, but the coagulopathy and endotheliopathy triggered by the cytokine storm represent possible target mechanisms.

© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

First appearing in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the 2019 coronavirus disease (COVID-19), which the World Health Organization (WHO) has declared a pandemic in MARS 2020.

Although the majority of the focus is on respiratory symptomatology, neurological complications, which are more frequent and complex than originally envisioned, may manifest subtly and add considerably to the severity of the disease [1,2].

✩ Competing Interests: The authors declare no conflicts of interest.
✩✩ Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
∗ Corresponding author.
E-mail address: hichambenramdane10@gmail.com (H. Benramdane).
https://doi.org/10.1016/j.radcr.2022.08.017
1930-0433/© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Acute ischemic stroke is an important but under-recognized neurovascular complication of SARS-CoV2 infection, with clinical presentations that vary widely from subject to subject [3,4].

A review of data from patients with COVID-19-associated stroke has highlighted specificities regarding disease mechanisms, patient demographics, but also clinical, biological, and neuroradiological specificities [5].

The pathogenesis and optimal management of COVID-19 associated ischemic stroke remain unclear, but emerging evidence suggests that cytokine storm-triggered coagulopathy and endotheliopathy represent possible targetable mechanisms [5].

### Cases presentation

This is a 44-year-old patient originating from Oujda (oriental of morocco) whose number of confirmed cases was 2860 with as dominant variant: the delta variant not vaccinated against COVID-19 due to the unavailability of the vaccine during the period of his admission, without any particular history, the history of the disease goes back 12 days before the date of her admission by the appearance of an influenza-like syndrome made of asthenia, myalgia, fever and cough.

The evolution was marked by the installation of a right hemiplegia 2 days after her admission neglected by the family and a respiratory discomfort motivating her consultation at the emergency room of the Mohammed VI University Hospital.

The clinical examination found a conscious patient, tachycardia at 125 bpm, BP = 140/65 mm Hg Polypneic at 30 cycles/min SpO2 at 60% on room air 80% under 15 L/min with signs of struggles. Neurological examination a right hemiplegia, without speech disorders, without cranial pairs involvement, with confusional syndrome and notion of auditory and visual hallucinations, fluctuating during the day, without meningeal stiffness or other associated signs. NIHSS: 10.

Patient hospitalized in the ICU and received and given the neurological and respiratory symptomatology the patient benefited from:

- C- brain CT showed hypodense left temporal and frontal cortico-subcortical areas associated with effacement of the cortical sulci opposite (Fig. 1). Cerebral MRI (Fig. 2) showed diffusion hypersignal with low ADC in the left temporal, left frontal and right frontal cortico-subcortical areas and left cerebellar punctiform. All lesions are in Flair and T2 hypersignal. No hemorrhagic stigma on the T2* sequence. Analysis of the 3D TOF sequence revealed a complete polygon of Willis without any image of stenosis. Minimal vascular leuкоpathy grade 1 according to the FAZEKAS scale: Multiple bilateral sylvian ischemic strokes and left PICA.
- Thoracic angioscan (Fig. 3) bilateral alveolar-interstitial lung disease suggestive of SARS COV-2 PNP classified as CORADS 5 with critical involvement (>-75%). Segmental pulmonary embolism in the right lower lobe and left upper lobe.

- Biological findings lymphopenia (900/μL NR: 1000-4000/μL), and elevation of D-Dimers at 35.2 mg/L (NR: 0-0.5mg/L), and given the pandemic context, an RT-PCR with COVID-19 was performed, which came back positive. The ECG showed no rhythm or conduction disorders Trans Thoracic Echocardiography was normal.

- The patient was put on: oxygen therapy (Optiflow), Azithromycin: 500 mg the first day then 250 mg for 6 days, Triaxone 2 g/d, Ciprofloxacin 200 mg/12 h, PPI 40 mg/d, Medrol 32 mg/d, Vit C 1 g x 2/d, Zinc 45 mg 1cp/d, Nicardipine (Loxen according to BP), Paracetamol 1g/6h if fever and curative anticoagulation Low Molecular Weight Heparin 6000 UI/12 h. On the neurological level, the patient was put on Levetiracetam: Keppra 250 mg: 0-0-1 for 03 days, then 1-0-1 for 03 days, then 1-0-2 for 03 days, then Keppra 500: 1-0-1, with monitoring of liver function, and Anti platelet therapy: Coplaxiv 75/100 mg: day for 03 weeks, then Kardégic 160 mg/d.

After a 12-day hospitalization in intensive care, the evolution was marked by a clinical and biological improvement.
Fig. 2 – Axial MRI sections in diffusion sequence (b)\(b'\)(b''), T2 FLAIR showing multiple bilateral sylvian subacute ischemic strokes and left PICA Absence of hemorrhagic remodeling. (c)(c')(c'').

The patient was discharged at home with good respiratory progress, and persistence of a sensory-motor deficit, then the patient was referred to a physical rehabilitation service.

**Discussion**

Most patients with ischemic stroke in COVID-19 were older than 60 years and had vascular risk factors. But, younger patients without known risk factors were also reported. These patients had predominantly large vessel occlusion, multiple vascular territory involvement, and neurological deficit that were severe at the time of presentation. Concomitant cases of deep vein thrombosis and pulmonary embolism were described. On the biological level, an elevation of D-dimer and inflammatory balance was marked as well as anti-phospholipid antibodies [5].

The authors also found that cryptogenic stroke was twice as common in COVID-19 positive patients compared with COVID-19 negative patients (65.6% vs 30.4%, respectively) [6], and it has been proposed that COVID-19-associated cryptogenic stroke represents a unique mechanism of stroke associated with a higher likelihood of early mortality [7,8].
The first study (Benali et al.) to link SARS-CoV-2 to acute stroke showed that COVID-19 infection was found to be independently and significantly associated with patients with acute ischemic stroke [9].

The pathogenesis of stroke during SARS-CoV-2 infection is complex and not fully understood, but current data indicate the combined effect of several factors, among them:

Infection results in the recruitment of mononuclear cells. These cells secrete pro-inflammatory cytokines (TNF-\(\alpha\), IL-1 and IL-6) that promote the release of plasminogen activator inhibitor (PAI-1) and inhibit natural anticoagulants. They promote the activation of coagulation through the generation of tissue factor, as well as the activation of platelets and their interaction with the activated endothelium [10].

The interaction between IL-6 secretion and the pro-coagulant phenotype of patients with SARS-CoV-2 is described in an Italian study with a significant association between fibrinogen and IL-6 levels [11]. This hyper-activation of coagulation is coupled with hypo-fibrinolysis. The role of fibrinolysis is to degrade fibrin, thanks to the action of plasmin. Plasmin is itself derived from plasminogen, and is dependent on tissue plasminogen activator and urokinase. Both of these enzymes are disrupted in inflammatory situations [12] and are inhibited by plasminogen activator inhibitor type I (PAI-1).

In SARS, high blood levels of PAI-1 were found in patients [13]. This hypofibrinolysis was further analyzed in critically ill COVID-19 patients, and it was shown in such a retrospective analysis comparing COVID-19 and non-COVID-19 patients...
that D-dimer and fibrinogen levels were higher in the former [13] and that COVID-19 stroke patients have dramatically elevated D-dimer and fibrinogen levels [14,15].

In addition to its role in thrombogenesis through activation and exposure of pro-thrombotic elements such as collagen, tissue factor, and platelet adhesion molecules [16]. Inflammation leads to instability and vulnerability to atherosclerotic plaque rupture. Inflammation and plaque vulnerability [17]. The presence of proteolytic enzymes such as metalloproteinases (MMPs) and cysteine proteases cathepsins (CCPs), which are secreted by the bloodstream, is a major factor in the development of inflammation. The presence of proteolytic enzymes such as metalloproteinases (MMPs) and cysteine proteases cathepsins (CCPs), which are secreted by activated macrophages, promote extracellular matrix degradation and plaque fragility and may lead to thromboembolism, while making acute ischemic stroke a likely event in the potential trajectories of patients with systemic COVID-19 infection [18]. This hyperinflammatory state is shown by marked increases in various biomarkers such as neutrophil/lymphocyte ratio (NLR), C-reactive protein, and serum ferritin in COVID-19 patients with DALYs [15,19]. In addition to CRP being a marker of inflammation, a meta-analysis also confirms its role in thromboembolic events [20]. On the other hand, serum ferritin, an inflammatory biomarker, also predicts the degree of neuronal damage in patients with AIS, as shown by its correlation with markers of blood-brain barrier damage such as glutamate, interleukin-6, metalloproteinase-9, and cellular fibronectin [21,22]. COVID-19 infection is also associated with deregulation of neutrophil extracellular traps (NETs) [23]. These traps are extracellular networks of chromatin, proteins, and oxidative enzymes produced by activated neutrophils and serve to contain infection, but they also play a role in thrombus formation [24]. There is evidence that in patients with COVID-19 infection, there is an increase in NET production that further propagates inflammation and thrombosis [6]. Evidence for the role of NETs in AIS is well described, Laridan et al examined thrombin from patients undergoing endovascular thrombectomy and found that Cit-H3, the hallmark of NETs, was observed in the majority of samples [25-27].

A characteristic feature of SARS-CoV2 infection is its interaction with ACE2 receptors, which significantly affect the RAAS [28]. This disruption of RAAS axes is likely to contribute to the pathogenesis of stroke by promoting inflammation, vasoconstriction, and organ damage [29].

Various COVID-19 registries have shown that there is an increased mortality rate in patients with preexisting cardiovascular disease such as hypertension and diabetes [30]. Similarly, a majority of AIS and COVID-19 patients report hypertension as a classic risk factor [31]. The contribution of hypertension to the outcomes of COVID-19 patients is likely explained by a variety of mechanisms. Nevertheless, classical RAAS overactivity as well as virus-induced endothelial vasoconstriction may be contributing factors to the neurological exacerbation of COVID infection [30].

It has been shown in recent publications that antiphospholipid antibodies are positive in patients severely infected with sars-CoV-2 and presenting with multiple stroke [15,32]. Thus, COVID-19 disease may trigger a transient or permanent antiphospholipid antibody syndrome resulting in vasculitis and cerebral and endothelial disease predisposing to a thromboembolic state. However, it is possible that SARS-CoV-2 interacts directly with cerebral endothelial cells that express the ACE-2 receptor leading to excessive and prolonged activation of the coagulation cascade, as well as activation of immune cells [33,34].

Conclusion

COVID-19 is a global pandemic caused by SARS-CoV-2 that is causing significant morbidity and mortality worldwide, making it the most significant health crisis of the decade.

And as the pandemic continues to grow, various neurological manifestations have become evident, among them ischemic strokes.

The COVID-19 virus has become a risk factor for stroke, especially in the absence of a pre-existing medical condition, which has proven to be very aggressive with a high case-fertility rate. Hence, the interest in systematically searching for an underlying viral infection such as COVID-19 in cryptogenic strokes.

Patient consent

Informed consent was obtained from the patient.

REFERENCES

[1] Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: a literature review. J Clin Neurosci 2020;77:8-12. doi: 10.1016/j.jocn.2020.05.017.
[2] Chen X, Laurent S, Onur OA, Kleineberg NN, Fink GR, Schweitzer F, et al. A systematic review of neurological symptoms and complications of COVID-19. J Neurol 2021;268(2):392-402. doi: 10.1007/s00415-020-10067-3.
[3] Wijeratne T, Sales C, Karimi L, Crewther SG. Acute ischemic stroke in COVID-19: a case-based systematic review. Front Neurol 2020;11. doi: 10.3389/fneur.2020.01031.
[4] Tungç A, Ünlübaş Y, Alemdar M, Akyüz E. Coexistence of COVID-19 and acute ischemic stroke report of four cases. J Clin Neurosci 2020;77:227-9. doi: 10.1016/j.jocn.2020.05.018.
[5] Vogrig A, Gigli GL, Bnà C, Morassi M. Stroke in patients with COVID-19: clinical and neuroimaging characteristics. Neurosci Lett 2021;743:135564. doi: 10.1016/j.neulet.2020.135564.
[6] Yaghi S, Ishida K, Torres J, Mac Gorry B, Raz E, Humbert K, et al. SARS-CoV-2 and stroke in a New York Healthcare System. Stroke 2020;51(7):2002–11. doi: 10.1161/STROKEAHA.120.030335.
[7] Siegler JE, Cardona P, Arenillas JF, Talavera B, Guillen AN, Chavarri-Varanda A, et al. Cerebrovascular events and outcomes in hospitalized patients with COVID-19: the SVIN COVID-19 Multinational Registry. Int J Stroke 2021;16(4):437-47. doi: 10.1177/1747493020959216.
[8] Zakeri A, Jadhav AP, Sullenger BA, Ninjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the
neurointerventionalist. J Neurointerv Surg 2021;13(3):202–6. doi:10.1136/neurintsurg-2020-016794.

[9] Belani P, Schefflein J, Khaira S, Rigney B, Delman BN, Mahmoudi K, et al. COVID-19 is an independent risk factor for acute ischemic stroke. AJNR Am J Neuroradiol 2020;41(8):1361–4. doi: 10.3174/ajnr.A6650.

[10] Bonny V, Maillard A, Mousseaux C, Plaçais L, Richier Q. COVID-19: pathology of a multi-faceted disease TT - COVID-19 : physiopathologie d’une maladie à plusieurs visages. La Rev Med Intern 2020;41(6):375–89. doi:10.1016/j.revm.2020.05.003.

[11] Ranucci M, Ballotta A, Di Dadda U, Baryshnikova E, Dei Poli M, Resta M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020;18(7):1747–51. doi:10.1111/jth.14854.

[12] Biemond B, Levi M, Ten Cate H, Van der Poll T, Büller HR, Hack CE, et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effects of interventions in the cytokine and coagulation cascades. Clin Sci (London) 1995;88(5):587–94. doi:10.1042/cs0880587.

[13] Wu WP, Wei R, Liu ZH, Chen B, Lisman T, Ren DL, et al. Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients. Thromb Haemost 2006;96(1):100–1. doi:10.1160/TH05-12-0827.

[14] Requena M, Olivé-Gadea M, Muchada M, García-Tornel A, Deck M, Juega J, et al. COVID-19 and stroke: incidence and etiological description in a high-volume center. J Stroke Cerebrovasc Dis. 2020;29(11):105225. doi:10.1016/j.jstrokecerebrovasdis.2020.105225.

[15] Beyrouti R, Adams ME, Benjamin L, Cohen H, Farmer SF, Goh YY, et al. Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry 2020;91(8):889–91. doi:10.1136/jnnp-2020-323586.

[16] de P Pereira M, Lima EG, Serrano Junior CV. Viral infections and atherothrombosis: another caution in the wake of COVID-19? Rev Assoc Med Bras 2020;66(3):366–9. doi:10.1590/1806-9282.66.3.366.

[17] Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med 2015;278(5):483–93. doi:10.1111/joim.12406.

[18] Camaré C, Fucelle M, Nègre-Salvayre A, Salvayre R. Angiogenesis in the atherosclerotic plaque. Redox Biol 2017;12:18–34. doi:10.1016/j.redox.2017.01.007.

[19] Avula A, Nalleballe K, Narula N, Sapozhnikov S, Dandu V, Toom S, et al. COVID-19 presenting as stroke. Brain Behav Immun 2020;87:115–19. doi:10.1016/j.bbi.2020.04.077.

[20] Kunutsor SK, Seidu S, Blom AW, Khunti K, Laukkanen JA. Serum C-reactive protein increases the risk of venous thromboembolism: a prospective study and meta-analysis of published prospective evidence. Eur J Epidemiol 2017;32(8):657–67. doi:10.1007/s10654-017-0277-4.

[21] Millán M, Sobrino T, Arenallos JJ, Rodríguez-Yáñez M, García M, Nombela F, et al. Biological signatures of brain damage associated with high serum ferritin levels in patients with acute ischemic stroke and thrombotic treatment. DisMarkers 2008;25(3):181–8. doi:10.1155/2008/380356.

[22] Zhang ZL, Hou YL, Li DT, Li FZ. Laboratory findings of COVID-19: a systematic review and meta-analysis. Scand J Clin Lab Invest 2020;80(6):441–7. doi:10.1080/00365513.2020.1768587.

[23] Middleton EA, He XY, Denorme F, Campbell RA, Ng D, Salvatore SP, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 2020;136(10):1169–79. doi:10.1182/blood.2020070008.

[24] Wijeratne T, Gillard Grewther S, Sales C, Karimí L. COVID-19 pathophysiology predicts that ischemic stroke occurrence is an expectation, not an exception—a systematic review. Front Neurol 2021;11:607221. doi:10.3389/fneur.2020.607221.

[25] Laridán E, Denorme F, Desender L, François O, Andersson T, Deckmyn H, et al. Neutrophil extracellular traps in ischemic stroke thrombi. Ann Neurol 2017;82(2):223–32. doi:10.1002/ana.24993.

[26] Lim HH, Jeong IH, An GD, Woo KS, Kim KH, Kim JM, et al. Evaluation of neutrophil extracellular traps as the circulating marker for patients with acute coronary syndrome and acute ischemic stroke. J Clin Lab Anal 2020;34(5):e23190. doi:10.1002/jcla.23190.

[27] Zhou P, Li T, Jin J, Liu Y, Li B, Sun Q, et al. Interactions between neutrophil extracellular traps and activated platelets enhance procoagulant activity in acute stroke patients with ICA occlusion. EBioMedicine 2020;53:102671. doi:10.1016/j.ebiom.2020.102671.

[28] Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol 2020;92(7):726–30. doi:10.1002/jmv.25785.

[29] Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. Transl Stroke Res 2020;11(3):322–5. doi:10.1007/s12975-020-00818-9.

[30] Huang S, Wang J, Liu F, Liu J, Cao G, Yang C, et al. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res 2020;43(8):824–31. doi:10.1007/s10992-020-0485-2.

[31] Tan YK, Goh C, Leow AST, Tambah PA, Ang A, Yap ES, et al. COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. J Thromb Thrombolysis 2020;50(3):587–95. doi:10.1007/s11239-020-02228-y.

[32] Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, et al. Lupus anticoagulant and abnormal coagulation tests in patients with COVID-19. N Engl J Med 2020;383(3):288–90. doi:10.1056/NEJMct2013656.

[33] B.E. AL, “‘COVID-19 et accident vasculaire cérébral: quel lien et quelles particularités diagnostiques et thérapeutiques?” 2020.

[34] Faraj R, Belkhayat C, Bouchlarhem A, El Aidouni G, Bkiyar H, Housni B. Acute pericarditis revealing COVID-19 infection: case report. Ann Med Surg (Lond) 2021;62:225–7. doi:10.1016/j.amsu.2021.01.053.